格隆汇2月24日丨宜安科技(300328.SZ)在互动平台表示，公司目前研发的用于医疗器械类的材料为生物 可降解高纯镁材料，暂未涉及生物相容性钛合金材料。 ...

证券日报网讯 2月24日，欧普康视（300595）在互动平台回答投资者提问时表示，公司的硬镜设计和生 产系统以及很多管理系统都应用了智能化技术，但不是大模型这类最新的工具。公司会不断应用新技术 提升公司的产品研发、生产、验配、售后服务、技术支持、质量管理等综合水平。 ...

Company Project Progress - The collaboration project with the Gates Foundation has advanced, with the development of ultrasound equipment's gestational age and fetal position functions completed and now entering clinical validation and confirmation stages. Three new automatic measurement functions in obstetrics are in the clinical data collection and performance optimization phase, which may impact the product launch timeline [1] Project Development - The overseas capacity layout has deepened, with a new facility in the U.S. (covering 1,940 square meters) fully certified as of July 2025. The company plans to flexibly arrange domestic and overseas capacity based on order demand, which is expected to enhance supply chain resilience in the long term. The main structure of the second-phase industrial building has been capped, and internal decoration is underway, with production capacity expected to ramp up in phases after launch [2] Strategic Advancement - The internationalization strategy is being continuously promoted, with plans to drive growth in international markets through product iteration upgrades and expanding local construction overseas, particularly in patient monitoring and ultrasound imaging businesses [3]

Group 1 - The FDA issued an early warning regarding a security vulnerability in the TRUE METRIX blood glucose meters from Trividia Health, a subsidiary of Sanofi, indicating 114 cases of serious injuries and 1 death reported [1] - The company has initiated corrective actions for product labeling and usage instructions, outlining a risk response plan [1] - This incident may have a short-term negative impact on the brand reputation and overseas business [1] Group 2 - As of February 24, 2026, Sanofi's stock price closed at 18.01 yuan, with a daily increase of 0.45% and a trading volume of 55.67 million yuan [2] - Over the past 5 days, the stock price has decreased by 1.10%, underperforming the market, with a net outflow of 6.05 million yuan in major funds, reflecting cautious market sentiment [2] - The company's share repurchase plan has been completed, with a total of 15.76 million shares repurchased, accounting for 2.81% of the total share capital, with a transaction amount of approximately 300 million yuan [2] Group 3 - Institutions maintain a neutral outlook on Sanofi, with a target price of 24.00 yuan, indicating a potential upside of 33.85% from the current stock price [3] - According to forecasts from 30 institutions, the net profit attributable to the parent company is expected to decline by 12.15% year-on-year in 2025, primarily due to patent and settlement costs [3] - A significant rebound is anticipated in 2026, with an expected year-on-year growth of 65.11%, driven by the expansion of CGM business and improvements in overseas operations [3]

证券研究报告 | 首次覆盖报告 gszqdatemark 2026 02 24 年 月 日 行业：丁腈手套综合性能优异，需求持续景气。丁腈手套过敏率低，综合 性能表现优异，可应用于医疗、工业、民用等各类使用场景，渗透率持续 提升。据马来西亚丁腈手套龙头贺特佳，25 年全球橡胶手套需求约 3250- 3750 亿只，未来有望保持大单位数增长趋势。从供需结构来看，欧美需求 占比约 60%；供给则集中在中国和马来西亚，各占比 30%-40%。我们预 计在需求稳健增长、供给集中度提升的背景下，行业竞争将进一步回归成 本与效率。 核心壁垒：技术领先+原材料自供/燃煤优势+规模效应，成本优势突出。 丁腈手套行业竞争充分，成本优势为核心。公司通过技术、原材料、能源 及规模四个维度构筑难以复制的成本壁垒：① 产线新、自动化水平高， 生产效率持续领先；② 原材料与能源合计占成本约 6-7 成，其中公司核 心原材料丁腈胶乳自供比例达 80%，低于同业的外采依赖；同时公司为主 要全球手套厂商中少数以燃煤为主要能源结构的企业，较天然气或外购蒸 汽具备明显成本优势；③ 公司已成为全球最大的丁腈手套生产商，扩产 仍在推进，规模效应有望进 ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向科华生物提问："近期中国国际医疗设备与器械交易（集采）平台在天津市揭牌 上线，将推动实现医疗设备与器械'全球买、全球卖'，贵司是否有关注，是否考虑通过该平台推广销售 公司产品。" 针对上述提问，科华生物回应称："尊敬的投资者，您好！公司会密切关注行业发展趋势和市场需求， 结合公司实际业务需要和发展战略，制定业务规划，积极把握业务机会。同时，公司会不断完善国内外 销售渠道和服务渠道，积极拓展国内外市场。感谢您的关注！" ...

国盛证券研报指出，英科医疗专注一次性手套的生产和销售，在近年全球公共卫生事件中已积累大量资 金并用于规模化扩产。2019年至2025H1，公司丁腈手套年化产能从190亿只增长至560亿只，已成为全 球丁腈手套龙头。长期来看，在行业供需趋于理性、竞争回归成本与效率的背景下，头部厂商的分化逻 辑愈发清晰。具备规模、成本与全球化能力的企业，有望持续提升份额。认为公司是本轮手套行业复苏 中确定性高、弹性优的核心受益标的，当前对应26年PE仅15.0X，首次覆盖予"买入"评级。 ...

华安中证全指医疗器械指数发起式A（021469）基金经理为苏卿云。 截至发稿，苏卿云累计任职时间9年70天，现任基金资产总规模100.51亿元，任职期间最佳基金回报 131%， 任职期间最差基金回报-62.44%。 2月24日，英科医疗涨5.08%，截至发稿，报41.35元/股，成交1.74亿元，换手率0.93%，总市值270.91亿 元。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 从基金十大重仓股角度 数据显示，华安基金旗下1只基金重仓英科医疗。华安中证全指医疗器械指数发起式A（021469）四季 度增持1200股，持有股数1.88万股，占基金净值比例为2.29%，位居第九大重仓股。根据测算，今日浮 盈赚取约3.76万元。 华安中证全指医疗器械指数发起式A（021469）成立日期2024年11月5日，最新规模1678 ...

经济观察网 根据2026年2月24日的市场数据，九安医疗股价表现强劲，盘中最高触及44.90元，收盘于 44.67元，单日涨幅达8.34%，突破了60日移动平均线（41.43元）。此次上涨主要受以下因素驱动： 2025年三季报显示，公司归母净利润同比增长16.11%至15.89亿元，主要受益于资产管理业务收益贡 献。华创证券指出，公司C端试剂盒业务在第三季度呈现环比增长，且新品研发（如CGM、四联检等） 持续推进。机构持仓方面，摩根医疗健康股票A在四季度增持九安医疗至62.42万股，占基金净值比例达 5.46%。 股价情况 股价突破布林带上轨（43.99元），MACD指标显示多头动能增强，KDJ指标中J线升至84.3，短期技术 面偏强。叠加所属医疗器械板块当日上涨0.69%，以及天津地域概念股表现活跃（涨1.55%），共同形 成催化。 以上内容基于公开资料整理，不构成投资建议。 资金面情况 当日主力资金净流入约9933.51万元，其中特大单买入占比显著，市场交投活跃，换手率达到5.03%。融 资融券方面，尽管2月13日出现融资净偿还，但当前融资余额11.11亿元占流通市值比例处于近一年较低 水平，可能为后续资 ...

Core Viewpoint - The medical device sector is experiencing a turning point, driven by performance recovery and innovation in overseas markets, with a focus on surgical robots, brain-computer interfaces, AI medical technology, and high-potential innovative devices like PFA, RDN, and TAVR [1] Group 1: Market Performance - As of February 24, 2026, the CSI Medical and Medical Device Innovation Index (931484) rose by 0.25%, with notable increases in component stocks such as Aier Eye Hospital (up 2.23%), Yingke Medical (up 1.96%), and Xingqi Eye Medicine (up 1.45%) [1] - The Medical Innovation ETF (516820) is currently in a state of market tension, with the latest quote at 0.36 yuan [1] Group 2: Industry Developments - Recent developments in the surgical robot sector, including successful bids from MicroPort Robotics and Aikang Medical, have significantly raised market expectations for the commercialization of related equipment [1] - Continued funding interest in cutting-edge areas such as AI medical technology and brain-computer interfaces is noted, alongside a U.S. court ruling that deemed tariff policies illegal, further strengthening the logic for medical device exports [1] Group 3: Index Composition - As of January 30, 2026, the top ten weighted stocks in the CSI Medical and Medical Device Innovation Index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]